| A clinician’s guide to perioperative bridging for patients on oral anticoagulation MT Martin, AM Kuchta, EA Nutescu Journal of Pharmacy Practice 23 (4), 303-312, 2010 | 10 | 2010 |
| A HIGH PERCENTAGE OF NEWLY INITIATED DIRECT ORAL ANTICOAGULANT USERS SWITCH BACK TO TRADITIONAL THERAPY BS Manzoor, TA Lee, L Sharp, WL Galanter, SM Walton, EA Nutescu VALUE IN HEALTH 20 (5), A10-A10, 2017 | | 2017 |
| A national survey of anticoagulation clinics on the use of brand versus generic warfarin R Bongiorno, E Nutescu Pharmacotherapy 19 (10), 1204, 1999 | 1 | 1999 |
| A new approach towards minimizing the risk of misdosing warfarin initiation doses A Sharabiani, EA Nutescu, WL Galanter, H Darabi Computational and mathematical methods in medicine 2018 (1), 5340845, 2018 | 10 | 2018 |
| A pharmacogenetics service experience for pharmacy students, residents, and fellows K Drozda, Y Labinov, R Jiang, MR Thomas, SS Wong, S Patel, ... American journal of pharmaceutical education 77 (8), 175, 2013 | 22 | 2013 |
| A pharmacologic overview of current and emerging anticoagulants. EA Nutescu, NL Shapiro, A Chevalier, AN Amin Cleveland Clinic journal of medicine 72, S2-6, 2005 | 84 | 2005 |
| A Risk Assessment Model for the Identification of Sickle Cell Disease Patients at Risk for Venous Thromboembolism J Zhou, GS Calip, EA Nutescu Blood 132, 3568, 2018 | | 2018 |
| A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery WB Balcom, DN Mishol, S Eapen, BK Bookhart, EA Nutescu, JR Schein, ... Current Orthopaedic Practice 23 (3), 221-228, 2012 | 1 | 2012 |
| Abstract P105: A Single-Center Experience with Low-Dose Warfarin in Patients Undergoing Total Hip or Total Knee Replacement Surgery WB Balcom, BK Bookhart, DN Mishol, S Eapen, EA Nutescu, JR Schein, ... Circulation: Cardiovascular Quality and Outcomes 4 (suppl_2), AP105-AP105, 2011 | | 2011 |
| Abstract P471: Citizenship Status and the Prevalence, Treatment, and Control of Cardiovascular Disease Risk Factors Among Immigrants in United States, 2011-2016 JS Guadamuz, RA Durazo-Arvizu, ML DAVIGLUS, G Calip, E Nutescu, ... Circulation 141 (Suppl_1), AP471-AP471, 2020 | 1 | 2020 |
| Abstract W P302: Assessment of a New Method of Warfarin Management vs the New Oral Anticoagulants and Conventional Warfarin Management in Atrial Fibrillation HI Bussey, E Nutescu Stroke 46 (suppl_1), AWP302-AWP302, 2015 | | 2015 |
| Addition of CYP2C9* 5,* 6,* 8,* 11 and rs12777823 genotypes into an existing warfarin dosing algorithm improves algorithm performance for African Americans. K Drozda, SR Patel, EA Nutescu, L Cavallari PHARMACOTHERAPY 34 (10), E220-E221, 2014 | | 2014 |
| Adherence and cumulative bisphosphonate dose in relation to risk of skeletal-related events among older patients with multiple myeloma. J Zhou, K Sweiss, PR Patel, E Nutescu, N Ko, BCH Chiu, GS Calip Journal of Clinical Oncology 37 (15_suppl), e18250-e18250, 2019 | | 2019 |
| Adherence and persistence with DPP-4 inhibitors versus pioglitazone in type 2 diabetes patients with chronic kidney disease: a retrospective claims database analysis D Gor, TA Lee, GT Schumock, SM Walton, BS Gerber, EA Nutescu, ... Journal of Managed Care & Specialty Pharmacy 26 (1), 67-75, 2020 | 10 | 2020 |
| All-cause and disease-related costs associated with recurrent venous thromboembolism P Lefebvre, F Laliberté, E Nutescu, MS Duh, JC LaMori, B Bookhart, ... Value in Health 16 (3), A187, 2013 | | 2013 |
| All-cause and disease-related health care costs associated with recurrent venous thromboembolism P Lefebvre, F Laliberté, EA Nutescu, MS Duh, J LaMori, BK Bookhart, ... Thrombosis and haemostasis 110 (12), 1288-1297, 2013 | 27 | 2013 |
| All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries P Lefebvre, F Laliberté, EA Nutescu, MS Duh, J LaMori, BK Bookhart, ... Journal of Managed Care Pharmacy 18 (5), 363-374, 2012 | 58 | 2012 |
| Anticoagulant agents are mainstay therapies in the prevention and treatment of arterial and venous thrombosis. Introduction. EA Nutescu The American Journal of Managed Care 12 (16 Suppl), S427-9, 2006 | | 2006 |
| Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a realworld setting: A proposal for a new pharmacogenetic dosing approach MJ Arwood, J Deng, K Drozda, O Pugach, EA Nutescu, S Schmidt, ... Clinical Pharmacology & Therapeutics 101 (5), 675-683, 2017 | 30 | 2017 |
| Anticoagulation in Long-Term Care: The State of the Art M Fraser, E Nutescu, LG Jacobs Journal of the American Medical Directors Association 3 (4), H17-H20, 2002 | 1 | 2002 |
William GalanterDept of Medicine, Univ of Illinois at Chicago在 uic.edu 的电子邮件经过验证
